Syngene International 

₹395.60
35
-₹5.20-1.3% Friday 09:59

Statistics

Day High
395.7
Day Low
395.1
52W High
678.95
52W Low
375.25
Volume
4,411
Avg. Volume
-
Mkt Cap
159.7B
P/E Ratio
53.48
Dividend Yield
0.32%
Dividend
1.25

Upcoming

Dividends

0.32%Dividend Yield
Jul 26
₹1.25
Jul 25
₹1.25
Jul 24
₹1.25
Aug 23
₹0.75
Aug 23
₹0.50
10Y Growth
2.26%
5Y Growth
N/A
3Y Growth
35.72%
1Y Growth
N/A

Earnings

21OctExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
0
1.53
3.07
4.6
Expected EPS
0.668486497068
Actual EPS
N/A

Financials

8.77%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
36.11BRevenue
3.17BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SYNGENE.NSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Syngene International Limited, an India-based contract research and manufacturing organization (CRAMO), offers a wide array of drug discovery and development solutions to clients across India, the United States, and other international markets. The company's comprehensive service portfolio begins with discovery chemistry, encompassing medicinal and synthetic chemistry, library and peptide synthesis, biomolecule research, organic electronic materials, and specialized computational and analytical chemistry. In discovery biology, capabilities extend to recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK (Drug Metabolism and Pharmacokinetics), in vivo pharmacology, toxicology, and the development of biologicals. Syngene provides a full spectrum of toxicology services, from exploratory and in vitro studies to genetic, developmental, and reproductive toxicology, alongside acute, sub-chronic, and chronic toxicity assessments. Their development services include chemical, formulation, analytical, and clinical development, as well as commercial manufacturing. They also support crucial stages like lead generation, preclinical development, API (Active Pharmaceutical Ingredient) synthesis, and finished drug product development. For clinical trials, Syngene offers robust support, covering trial management, pharmacokinetic analysis/bioanalytical services, central laboratory operations, biometrics and clinical data management, regulatory affairs, medical monitoring, pharmacovigilance, and medical writing. Additionally, the company specializes in emerging drug modalities, such as peptides, oligonucleotide synthesis, antibody-drug conjugates (ADCs), PROTACs, and CAR T-cell therapies. Serving a diverse clientele that spans pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical industries, Syngene has established key collaborations with entities like Bristol-Myers Squibb Co., Baxter Inc., and Amgen Inc. Incorporated in 1993 and headquartered in Bengaluru, India, Syngene International Limited operates as a subsidiary of Biocon Limited.
Show more...
CEO
Siddharth Mittal
Employees
6692
Country
India
ISIN
INE398R01022

Listings

0 Comments

Share your thoughts

FAQ

What is Syngene International stock price today?
The current price of SYNGENE.NSE is ₹395.60 INR — it has decreased by -1.3% in the past 24 hours. Watch Syngene International stock price performance more closely on the chart.
What is Syngene International stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on NSE (India) exchange Syngene International stocks are traded under the ticker SYNGENE.NSE.
Is Syngene International stock price growing?
SYNGENE.NSE stock has fallen by -1.93% compared to the previous week, the month change is a -1.04% fall, over the last year Syngene International has showed a -38.99% decrease.
What is Syngene International market cap?
Today Syngene International has the market capitalization of 159.7B
When is the next Syngene International earnings date?
Syngene International is going to release the next earnings report on October 21, 2026.
What were Syngene International earnings last quarter?
SYNGENE.NSE earnings for the last quarter are 0 INR per share, whereas the estimation was 1.45 INR resulting in a -100% surprise. The estimated earnings for the next quarter are N/A INR per share.
What is Syngene International revenue for the last year?
Syngene International revenue for the last year amounts to 36.11B INR.
What is Syngene International net income for the last year?
SYNGENE.NSE net income for the last year is 3.17B INR.
Does Syngene International pay dividends?
Yes, SYNGENE.NSE dividends are paid annual. The last dividend per share was 1.25 INR. As of today, Dividend Yield (FWD)% is 0.32%.
How many employees does Syngene International have?
As of September 06, 2026, the company has 6,692 employees.
In which sector is Syngene International located?
Syngene International operates in the Health & Wellness sector.
When did Syngene International complete a stock split?
The last stock split for Syngene International was on June 11, 2019 with a ratio of 1:1.
Where is Syngene International headquartered?
Syngene International is headquartered in Bengaluru, India.